Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

Core Insights - Lisata Therapeutics, Inc. is set to report its financial results for Q3 2025 on November 6, 2025, after market close, followed by a conference call at 4:30 p.m. Eastern time [1] Company Overview - Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [3] - The company's lead product candidate, certepetide, is designed to enhance the delivery of anti-cancer drugs to solid tumors through a novel uptake pathway [3] - Lisata has established significant commercial and R&D partnerships based on its CendR Platform® technology [3] - The company anticipates announcing multiple milestones over the next 1.5 years and projects that its capital will support operations into Q1 2027, including data milestones from ongoing clinical trials [3]